相关实验视频
Updated: Jun 13, 2025

06:26
Novel and Innovative Hybrid Technique for Type A Aortic Dissection
Published on: March 28, 2025
211
作为非综合征患者高血压患者大动脉剖析的初级和二级预防的β-阻塞剂
Mads Liisberg1,2,3, Jes S Lindholt1,2, Katrine L Larsen1,2,3
1Department of Cardiothoracic and Vascular Surgery University Hospital Odense Odense Denmark.
Journal of the American Heart Association
|June 11, 2025
概括
β阻塞剂没有降低大动脉剖析风险,也没有提高高血压患者的生存率. 这项研究挑战了目前的指导方针,并表明需要进一步的研究.
科学领域:
- 心脏病学 心脏病学
- 血管医学 血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 目前对β阻塞剂用于预防大动脉解剖 (AD) 和改善存活率的建议是基于有限的证据.
- 患有高血压的非综合症患者是这些建议的重点.
研究的目的:
- 调查长期使用β阻塞剂与阿尔茨海默病风险之间的关联.
- 为了评估β阻塞剂使用对剖析后存活率的影响.
主要方法:
- 一项全国性的基于人口的研究,使用嵌套病例控制和历史队列设计.
- 从1996年到2016年,丹麦的医疗保健注册表被用于识别和验证成年AD患者.
- 排除标准包括双主动脉或连接组织疾病. 病例控制分析涉及1657个AD病例与16,139个高血压对照匹配. 队列分析对2120名阿尔茨海默病幸存者进行了5年的跟踪.
主要成果:
- 长期使用β抑制剂与AD型A (aOR,1.7) 和B型 (aOR,3.7) 的几率增加有关.
- 观察到AD型B的风险增加取决于剂量.
- 贝塔抑制剂的使用与阿尔茨海默病A型 (aHR,1.5) 和B型 (aHR,1.5) 的幸存者在5年内全因死亡率较高有关.
结论:
- 与其他抗高血压药物相比,使用β阻塞剂并没有降低AD风险或改善幸存者的结局.
- 这些发现挑战了当前关于在高血压和AD中使用β阻塞剂的临床实践.
- 该研究强调需要随机试验来证实这些发现,尽管现有临床数据的局限性.
相关概念视频
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
542
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
542
Antihypertensive Drugs: Types of β-Blockers
600
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
600
Adrenergic Antagonists: ɑ and β-Receptor Blockers
420
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
420
Heart Failure Drugs: β-Blockers
320
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
320
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
547
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
547
Antianginal Drugs: Nitrates and β-Blockers
540
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
540

